Para más información científica puede
consultar los numerosos estudios, en inglés, que hemos recopilado en el Database on Clinical Studies and Case Reports
·
Mejoría sintomática o
evaluación positiva por parte de los autores
o
Sin cambio sintomático o evaluación negativa por parte de los autores
v
Empeoramiento de los síntomas
·
Artim R, DiBella N. Tetrahydrocannabinol (THC) plus prochlorperazine (PCZ)
for refractory nausea and vomiting (N/V). Proceedings of the American
Society for Clinical Oncology 1983;2:84.
·
Chang AE, Shiling DJ, Stillman RC, Goldberg NH, Seipp CA, Barofsky I.
Delta-9-tetrahydrocannabinol as an antiemetics in cancer patients receiving
high-dose methotrexate. Annals of Internal Medicine 1979;91:819-824.
o
Chang AE, Shiling DJ, Stillman RC, Goldberg NH, Seipp CA, Barofsky I,
Rosenberg SA.. A prospective evaluation of delta-9-tetrahydrocannabinol as an
antiemetic in patients receiving adriamycin and cytoxan chemotherapy. Cancer
1981; 47: 1746-1751.
·
Colls BM, Ferry DG, Gray AJ, Harvey VJ, McQueen EG. The antiemetic
activity of tetrahydrocanabinol versus metoclopramide and thiethylperazine in
patients undergoing cancer chemotherapy. New Zealand Medical Journal
1980;91:449-451.
·
Ekert H, Waters KD, Jurk KH, Mobilia J, Loughnan P. Ameriloration of
cancer chemotherapy-induced nausea and vomiting by
delta-9-tetrahydrocannabinol. Medical Journal of Australia 1979;2:657-659.
·
Frytak S, Moertel CG, O'Fallon JR, Rubin J, Creagan ET, O'Connnell MJ.
Delta-9-tetrahydrocannabinol as an antiemetics for patients receiving cancer
chemotherapy. A comparison with prochlorperazine and a placebo. Annals of
Internal Medicine 1979;91:825-830.
·
Gralla RJ, Tyson LB, Bordin LA, Clark RA, Kelsen DP, Kris MG. Antiemetic
therapy: a review of recent studies and a report of a random assignment trial
comparing metoclopramide with delta-9-tetrahydrocannabinol. Cancer Treatment
Report 1984;68:163-172.
·
Kluin-Nelemans JC, Nelemans FA, Meuwissen OJATh, Maes RAA. D9-tetrahydrocannabinol
(THC) as an antiemetic in patients treated with cancer chemotherapy; a
double-blind cross-over trial against placebo. Veterinary and Human Toxicology
1979;21:338-340.
·
Lane M, Vogel CL, Ferguson J, Krasnow S, Saiers JL, Hamm J. Dronabinol
and prochlorperazine in combination for treatment of cancer
chemotherapy-induced nausea and vomiting. Journal of Pain and Symptom
Management 1991;6:352-359.
·
Levitt M, Faiman C, Hawks R, Wilson A. Randomized double blind
comparison of delta-9-tetrahydroicannabinol (THC) and marijuana as chemotherapy
antiemetics. Proceedings of the American Society for Clinical Oncology
1984;3:91.
·
Levitt M, Wilson A, Bowman D, Faiman C, Kemel S, Krepart G. Dose vs
response of tetrahydroannabinol (THC) vs prochlorperazine as chemotherapy
antiemetics. Proceedings of the American Society for Clinical Oncology
1981;22:422.
·
McCabe M, Smith FP, Goldberg D, Macdonald J, Woolley PV, Warren R.
Efficacy of tetrahydrocannabinol in patients refractory to standard anti-emetic
therapy. Investigational New Drugs 1988;6:243-246.
·
Neidhart JA, Gagen MM, Wilson HE, Young DC. Comparative trial of the
antiemetic effects of THC and haloperidol. International Journal of Clinical
Pharmacology Research 1981; 21: 38-42S.
·
Orr LE, McKernan JF, Bloome B. Antiemetic effect of
tetrahydrocannabinol. Compared with placebo and prochlorperazine in
chemotherapy-associated nausea and emesis. Archives of Internal Medicine
1980;140:1431-433.
·
Sallan SE, Cronin C, Zelen M, Zinberg NE. Antiemetics in patients
receiving chemotherapy for cancer. A randomized comparison of
delta-9-tetrahydrocannabinol and prochlorperazine. New England Journal of
Medicine 1980;302:135-138.
·
Sallan SE, Zinberg NE, Frei E. Antiemetic effect of
delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. New
England Journal of Medicine 1975;293:795-797.
·
Ungerleider JT, Andrysiak T, Fairbanks L, Goodnight J, Sarna G, Jamison
K. Cannabis and cancer chemotherapy. A comparison of oral delta-9-THC and
prochlorperazine. Cancer 1982;50:636-645.
·
Ungerleider JT, Sarna G, Fairbanks LA, Goodnight J, Andrysiak T, Jamison
K. THC or compazine for the cancer chemotherapy patient - the UCLA study. Part
II: patient drug preference. American Journal of Clinical Oncology 1985; 8:
142-147.
·
Meiri E, Jhangiani H, Vredenburgh JJ, Barbato LM, Carter FJ, Yang HM,
Baranowski V. Efficacy of dronabinol alone and in combination with ondansetron
versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting.
Curr Med Res Opin 2007;23(3):533-43.
·
Levitt M, Faiman C, Hawks R, Wilson A. Randomized double blind
comparison of delta-9-tetrahydroicannabinol (THC) and marijuana as chemotherapy
antiemetics. Proceedings of the American Society for Clinical Oncology
1984;3:91.
·
Ahmedzai S, Carlyle DL, Clader IT, Moran F. Anti-emetic efficacy and
toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy.
British Journal of Cancer 1983;48:657-663.
·
Chan HS, Correia JA, MacLeod SM. Nabilone versus prochlorperazine for control of
cancer chemotherapy-induced emesis in children: a double-blind, crossover
trial. Pediatrics 1987; 79: 946-952
·
Crawford SM, Buckman R. Nabilone and metoclopramide in the treatment of
nausea and vomiting due to cisplatinum: a double blind study. Medical Oncology
and Tumor Pharmacotherapy 1986; 3: 39-42.
·
Cunningham D, Bradley CJ, Forrest GJ, Hutcheon AW, Adams L, Sneddon M,
et al. A randomized trial of oral nabilone and prochlorperazine compared to
intravenous metoclopramide and dexamethasone in the treatment of nausea and vomiting
induced by chemotherapy regimens containing cisplatin or cisplatin analogues.
European Journal of Cancer and Clinical Oncology 1988; 24: 685-689.
·
Dalzell AM, Bartlett H,
Lilleyman JS. Nabilone: An alternative antiemetic for cancer chemotherapy. Archives of
Disease in Childhood 1986;61:502-505.
·
Einhorn LH, Nagy C, Furnas B, Williams SD. Nabilone: an effective
antiemetic in patients receiving cancer chemotherapy. Journal of Clinical
Pharmacology. 1981 Aug-Sep;21(8-9 Suppl):64S-69S.
·
George M, Pejovic MH, Thuaire M, Kramar A, Wolff JP. Randomized
comparative trial of a new anti-emetic: nabilone, in cancer patients treated
with cisplatin. Biomedicine and Pharmacotherapy 1983; 37: 24-27.
·
Herman TS, Einhorn LH,
Jones SE, Nagy C, Chester AB, Dean JC, et al. Superiority of nabilone over
prochlorperazine as an antiemetic in patients receiving cancer chemotherapy.
New England Journal of Medicine 1979; 300: 1295-1297.
·
Johansson R, Kilkku P, Groenroos M. A double-blind, controlled trial of
nabilone vs prochlorperazine for refractory emesis induced by cancer
chemotherapy. Cancer Treatment Reviews 1982; 9: 25-33.
·
Jones SE, Durant JR, Greco FA, Robertone A. A multi-institutional phase
III study of nabilone vs placebo in chemotherapy-induced nausea and vomiting.
Cancer Treatment Reviews 1982; 9: 45-48
·
Levitt M. Nabilone vs placebo in the treatment of chemotherapy-induced
nausea and vomiting in cancer patients. Cancer Treatment Reviews 1982; 9(suppl
B): 49-53.
·
Nagy CM, Furnas BE, Einhorn LH, Bond WH. Nabilone: antiemetic crossover
study in cancer chemoptherapy patients. Proceedings of the American Society for
Cancer Research 1978;19:30.
·
Niederle N, Schutte J,
Schmidt CG. Crossover comparison of the antiemetic efficacy of nabilone and
alizapride in patients with nonseminomatous testicular cancer receiving
cisplatin therapy. Klinische Wochenschrift 1986; 64: 362-365.
·
Niiranen Aila, Mattson K. A cross-over comparison of nabilone and
prochlorperazine for emesis induced by cancer chemotherapy. American Journal of
Clinical Oncology 1985;8:336-340.
·
Pomeroy M, Fennelly JJ, Towers M. Prospective randomized double-blind
trial of nabilone versus domperidone in the treatment of cytotoxic-induced
emesis. Cancer Chemotherapy and Pharmacology 1986;17:285-288.
·
Priestman SG, Priestman TJ, Canney PA. A double-blind randomised
cross-over comparison of nabilone and metoclopramide in the control of
radiation-induced nausea. Clinical Radiology 1987; 38: 543-544.
·
Steele N, Gralla RJ, Braun Jr DW, Young CW. Double-blind comparison of
the antiemetic effects of nabilone and prochlorperazine on chemotherapy-induced
emesis. Cancer Treatment Report 1980; 64: 219-224.
·
Wada JK, Bogdon DL, Gunnell JC, Hum GJ, Gota CH, Rieth TE. Double-blind,
randomized, crossover trial of nabilone vs. placebo in cancer chemotherapy.
Cancer Treatment Reviews 1982; 9(Suppl B): 39-44
·
Citron ML, Herman TS, Vreeland F, Krasnow SH, Fossieck BE, Jr.
Antiemetic efficacy of levonantradol compared to delta-9-tetrahydrocannabinol
for chemotherapy-induced nausea and vomiting. Cancer Treatment Reports
1985;69:109-112.
·
Higi M, Niederle N,
Bremer K, Schmitt G, Schmidt CG, Seeber S. Levonantradol bei der Behandlung von
zytostatika-bedingter Nausea and Vomiting. Deutsche Medizinische Wochenschrift
1982; 107: 1232-1234.
·
Hutcheon AW, Palmer JB,
Soukop M, Cunningham D, McArdle C, Welsh J, et al. A randomised multicentre
single blind comparison of a cannabinoid anti-emetic (levonantradol) with
ychlorpromazine in patients receiving their first cytotoxic chemotherapy.
European Journal for Cancer and Clinical Oncology 1983; 19: 1087-1090
·
Stambaugh Jr JE, McAdams J, Vreeland F. Dose ranging evaluation of the
antiemetic efficacy and toxicity of intramuscular levonantradol in cancer
subjects with chemotherapy-induced emesis. International Journal of Clinical
Pharmacology Research1984; 24: 480-485
·
Abrahamov A, Abrahamov A, Mechoulam R. An efficient new cannabinoid
antiemetic in pediatric oncology. Life Sciences 1995;56:2097-2102.
·
Vinciguerra V, Moore T, Brennan E. Inhalation marijuana as an antiemetic
for cancer chemotherapy. New York State Journal of Medicine 1988;88:525-527.
·
Musty RE, Rossi R. Effects of smoked cannabis and oral
delta-9-tetrahydrocannabinol on nausea and emesis after cancer chemotherapy: A
review of state clinical trials. J Cannabis Ther 2001;1(1):29-42.
·
Doblin RE, Kleiman MA. Marijuana as antiemetic medicine: a survey of oncologists'
experiences and attitudes. American Journal of Clinical Oncology 1991; 9:
1314-1319.
o
Schwartz RH, Voth EA, Sheridan MJ. Marijuana to prevent nausea and
vomiting in cancer patients: a survey of clinical oncologists. South Medical
Journal 1997;90(2):167-72.
·
Ungerleider JT, Andrysiak TA, Fairbanks LA,
Tesler AS, Parker RG. Tetrahydrocannabinol vs. prochlorperazine. The effects of
two antiemetics on patients undergoing radiotherapy. Radiology
1984;150(2):598-9.
·
Lucraft HH, Palmer MK. Randomised clinical trial of levonantradol and
chlorpromazine in the prevention of radiotherapy-induced vomiting. Clinical
Radiology 1982; 33: 621-622.
·
Zutt M, Hanssle H, Emmert S, Neumann C, Kretschmer L. [Dronabinol for
supportive therapy in patients with malignant melanoma and liver metastases]
[Article in German]. Hautarzt 2006;57(5):423-7.
·
Gonzalez-Rosales F, Walsh D. Intractable nausea and vomiting due to
gastrointestinal mucosal metastases relieved by tetrahydrocannabinol
(dronabinol). Journal of Pain and Symptom Management 1997;14(5):311-314.
·
Layeeque R, Siegel E, Kass R, Henry-Tillman RS, Colvert M, Mancino A,
Klimberg VS. Prevention of nausea and vomiting following breast surgery. Am J Surg 2006;191(6):767-72.
·
Lewis IH, Campbell DN, Barrowcliffe MP. Effect of nabilone on nausea and
vomiting after total abdominal hysterectomy. British Journal of Anaesthesia
1994; 73: 244-246.
·
de Jong BC, Prentiss D, McFarland W, Machekano R, Israelski DM. Marijuana use and
its association with adherence to antiretroviral therapy among HIV-infected persons with moderate to severe
nausea. J
Acquir Immune Defic Syndr 2005;38(1):43-6.
·
Woolridge E, Barton S, Samuel J, Osorio J, Dougherty A, Holdcroft A.
Cannabis use in HIV for pain and other medical symptoms. J Pain Symptom Manage
2005;29(4):358-67.
·
Sidney S. Marijuana use in HIV-positive and AIDS patients: Results of a
an anonymous mail survey. J Cannabis Ther 2001;1(3-4):35-43.
·
Costiniuk CT, Mills E, Cooper CL. Evaluation of oral
cannabinoid-containing medications for the management of interferon and
ribavirin-induced anorexia, nausea and weight loss in patients treated for
chronic hepatitis C virus. Can J Gastroenterol 2008;22(4):376-80.
·
Sylvestre DL, Clements BJ, Malibu Y. Cannabis use improves retention and
virological outcomes in patients treated for hepatitis C. Eur J Gastroenterol
Hepatol 2006;18(10):1057-63.
·
Curry W-NL. Hyperemesis gravidarum and clinical cannabis: To eat or not to eat? J
Cannabis Ther 2002;2(3-4):63-83.
·
Westfall RE, Janssen PA, Lucas P, Capler R. Survey of medicinal cannabis
use among childbearing women: patterns of its use in pregnancy and retroactive
self-assessment of its efficacy against 'morning sickness'. Complement Ther
Clin Pract 2006;12(1):27-33.
·
Merriman AR, Oliak DA. Use of medical marijuana for treatment of severe
intractable nausea after laparoscopic Roux-en-Y gastric bypass surgery: case
report. Surg Obes Relat Dis, 26 January 2008 [Electronic publication ahead of
print])
·
Soderpalm AH, Schuster A, de Wit H. Antiemetic efficacy of smoked marijuana:
subjective and behavioral effects on nausea induced by syrup of ipecac.
Pharmacology, Biochemistry and Behavior
2001;69(3-4):343-50.
·
Beal JE, Olson R, Laubenstein L, Morales JP, Bellman P, Yangco B, Lefkowitz
L, Plasse TF, Shepard KV. Dronabinol as a treatment for anorexia associated with
weight loss in patients with AIDS. Journal of Pain and Symptom Management
1995;10(2):89-97.
·
Timpone JG, Wright DJ, Li N, Egorin MJ, Enama ME, Mayers J, Galetto G,
and the DATRI 004 Study Group. The safety and pharmacokinetics of single-agent
and combination therapy with megestrol acetate and dronabinol for the treatment
of HIV wasting syndrome. AIDS Research and Human Retroviruses 1997;13:305-315.
·
Abrams DI, Hilton JF, Leiser RJ, Shade SB, Elbeik TA, Aweeka FT,
Benowitz NL, Bredt BM, Kosel B, Aberg JA, Deeks SG, Mitchell TF, Mulligan K,
Bacchetti P, McCune JM, Schambelan M. Short-term effects of cannabinoids in
patients with HIV-1 infection: a randomized, placebo-controlled clinical
trial. Ann Intern Med 2003;139(4):258-66.
·
Haney M, Rabkin J, Gunderson E, Foltin RW. Dronabinol and marijuana in
HIV(+) marijuana smokers: acute effects on caloric intake and mood.
Psychopharmacology (Berl) 2005;181(1):170-8.
·
Haney M, Gunderson EW, Rabkin J, Hart CL, Vosburg SK, Comer SD, Foltin
RW. Dronabinol and marijuana in HIV-positive marijuana smokers. Caloric intake,
mood, and sleep. J Acquir Immune Defic Syndr 2007;45(5):545-54.
·
Haney M, Rabkin J, Gunderson E, Foltin RW. Dronabinol and marijuana in
HIV(+) marijuana smokers: acute effects on caloric intake and mood.
Psychopharmacology (Berl) 2005;181(1):170-8.
·
Haney M, Gunderson EW, Rabkin J, Hart CL, Vosburg SK, Comer SD, Foltin
RW. Dronabinol and marijuana in HIV-positive marijuana smokers. Caloric intake,
mood, and sleep. J Acquir Immune Defic Syndr 2007;45(5):545-54.
·
Gorter R, Seefried M, Volberding P. Dronabinol effects on weight in
patients with HIV infection. AIDS 1992;6:127.
·
Plasse TF, Gorter RW, Krasnow SH, Lane M, Shepard KV, Wadleigh RG.
Recent clinical experience with dronabinol. Pharmacology, Biochemistry and
Behavior 1991;40:695-700.
·
Plasse T, Conant M, Gorter R, Shepard KV. Dronabinol stimulates appetite
and causes weight gain in HIV patients. International Conference on AIDS
1992;8(3):122 (abstract no. PuB 7442).
·
Struwe M, Kaempfer SH, Geiger CJ, Pavia AT, Plasse TF, Shepard KV, Ries
K, Evans TG. Effect of dronabinol on nutritional status in HIV infection.
Annals of Pharmacotherapy 1993;27:827-831.
·
Beal JE, Olson R, Lefkowitz L, Laubenstein L, Bellman P, Yangco B,
Morales JO, Murphy R, Powderly W, Plasse TF, Mosdell KW, Shepard KV. Long-term efficacy
and safety of dronabinol for acquired immunodeficiency syndrome-associated
anorexia. Journal of Pain and Symptom Management 1997;14(1):7-14.
·
Dejesus E, Rodwick BM, Bowers D, Cohen CJ, Pearce D. Use of dronabinol
improves appetite and reverses weight loss in HIV/AIDS-infected patients. J Int
Assoc Physicians AIDS Care 2007;6(2):95-100.
·
Prentiss D, Power R, Balmas G, Tzuang G, Israelski DM. Patterns of
marijuana use among patients with HIV/AIDS followed in a public health care
setting. J
Acquir Immune Defic Syndr 2004;35(1):38-45.
·
Woolridge E, Barton S, Samuel J, Osorio J, Dougherty A, Holdcroft A.
Cannabis use in HIV for pain and other medical symptoms. J Pain Symptom Manage
2005;29(4):358-67.
·
Sidney S. Marijuana use in HIV-positive and AIDS patients: Results of a
an anonymous mail survey. J Cannabis Ther 2001;1(3-4):35-43.
·
Jatoi A, Windschitl HE, Loprinzi CL, Sloan JA, Dakhil SR, Mailliard JA,
Pundaleeka S, Kardinal CG, Fitch TR, Krook JE, Novotny PJ, Christensen B.
Dronabinol versus megestrol acetate versus combination therapy for
cancer-associated anorexia: a North Central Cancer Treatment Group study. Journal of Clinical
Oncology 2002;20(2):567-573.
·
Regelson W, Butler JR,
Schulz J, Kirk T, Peek L, Green ML, Zalis MO. Delta-9-tetrahydrocannabinol
as an effective antidepressant and appetite-stimulating agent in advanced
cancer patients. In: Braude MC, Szara S, editors. Pharmacology of marihuana.
Vol 2. New York: Raven Press, 1976. p. 763-776.
·
Wadleigh R, Spaulding GM, Lumbersky B, Zimmer M, Shepard K, Plasse T.
Dronabinol enhancement of appetite in cancer patients. Proc Am Soc Oncology
1990; 9: 331.
o
Strasser F, Luftner D, Possinger K, Ernst G, Ruhstaller T, Meissner W,
Ko YD, Schnelle M, Reif M, Cerny T. Comparison of orally administered cannabis
extract and delta-9-tetrahydrocannabinol in treating patients with
cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized,
double-blind, placebo-controlled clinical trial from the
Cannabis-in-Cachexia-Study-Group. J Clin Oncol 2006;24(21):3394-400.
o
Strasser F, Luftner D, Possinger K, Ernst G, Ruhstaller T, Meissner W,
Ko YD, Schnelle M, Reif M, Cerny T. Comparison of orally administered cannabis
extract and delta-9-tetrahydrocannabinol in treating patients with
cancer-related anorexia-cachexia syndrome: a multicenter, phase III,
randomized, double-blind, placebo-controlled clinical trial from the Cannabis-in-Cachexia-Study-Group.
J Clin Oncol
2006;24(21):3394-400.
·
Plasse TF, Gorter RW, Krasnow SH, Lane M, Shepard KV, Wadleigh RG.
Recent clinical experience with dronabinol. Pharmacology, Biochemistry and
Behavior 1991;40:695-700.
·
Nelson K, Walsh D, Deeter P, Sheehan F. A phase II study of
delta-9-tetrahydrocannabinol for appetite stimulation in cancer-associated
anorexia. Journal of Palliative Care 1994;10:14-18.
·
Volicer L, Stelly M, Morris J, McLaughlin J, Volicer BJ. Effects of
dronabinol on anorexia and disturbed behavior in patients with Alzheimer's
disease. International Journal of Geriatric Psychiatry 1997;12:913-919.
·
Patel S, Shua-Haim JR, Pass M. Safety and efficacy of dronabinol in the
treatment of agitation in patients with Alzheimer’s disease with anorexia: A retrospective
chart review. Abstract, 11th International Conference of the IPA, 17-22 August
2003, Chicago.
·
Wilson MM, Philpot C, Morley JE. Anorexia of aging in long term care: is
dronabinol an effective appetite stimulant? - a pilot study. J Nutr Health
Aging 2007;11(2):195-8.
o
Gross H, Ebert MH, Faden VB, Goldberg SC, Kaye WH, Caine ED, Hawks R,
Zinberg N. A double-blind trial of delta 9-tetrahydrocannabinol in primary
anorexia nervosa. Journal of Clinical Psychopharmacology 1983;3(3):165-171.
·
Bergmann K-C. [Dronabinol, a
possible new therapeutic option in patients with COPD and pulmonal cachexia]
[Article in German]. Abstract, 2005 Conference of the German Society for
Pneumology, 17 March 2005, Berlin.
·
Foltin RW, Fishman MW, Brady JV. Behavioral analysis of marijuana
effects on food intake in humans. Pharmacology, Biochemistry and Behavior
1986;25:577-582.
·
Foltin RW, Fischman MW,
Byrne MF. Effects of smoked marijuana on food intake and body weight of humans living
in a residential laboratory. Appetite 1988;11(1):1-14.
o
Killestein J, Hoogervorst EL, Reif M, Kalkers NF, Van Loenen AC, Staats PG,
Gorter RW, Uitdehaag BM, Polman CH. Safety, tolerability, and efficacy of orally
administered cannabinoids in MS. Neurology 2002;58(9):1404-7.
·
Petro DJ, Ellenberger C. Treatment of human spasticity with D9-tetrahydrocannabinol.
Journal of Clinical Pharmacology 1981;(Suppl 21):413S-416S.
·
Ungerleider JT,
Andyrsiak T, Fairbanks L, Ellison GW, Myers LW. D9-THC in the
treatment of spasticity associated with multiple sclerosis. Advances in Alcohol
and Substance Abuse 1987;7:39-50.
·
Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, Thompson A, on
behalf of the UK MS Research Group. Cannabinoids for treatment of spasticity
and other symptoms related to multiple sclerosis (CAMS study): multicentre
randomised placebo-controlled trial. Lancet 2003; 362(9385): 1517-1526.
·
Zajicek JP, Sanders HP, Wright DE, Vickery PJ, Ingram WM, Reilly SM,
Nunn AJ, Teare LJ, Fox PJ, Thompson AJ. Cannabinoids in multiple sclerosis
(CAMS) study: safety and efficacy data for 12 months follow up. J Neurol
Neurosurg Psychiatry 2005;76(12):1664-9.
·
Martyn CN, Illis LS, Thom J. Nabilone in the treatment of multiple
sclerosis. Lancet 1995;345:579.
·
Vaney C, Heinzel-Gutenbrunner M, Jobin P, Tschopp F, Gattlen B, Hagen U,
Schnelle M, Reif M. Efficacy of tetrahydrocannabinol in patients refractory to
standard antiemetic therapy.Efficacy, safety and tolerability of an orally
administered cannabis extract in the treatment of spasticity in patients with
multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover
study. Multiple Sclerosis 2004;10(4):417-24.
·
Wade DT, Makela P, Robson P, House H, Bateman C. Do cannabis-based
medicinal extracts have general or specific effects on symptoms in multiple
sclerosis? A double-blind, randomized, placebo-controlled study on 160
patients. Multiple Sclerosis 2004;10(4):434-41.
·
Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, Thompson A, on
behalf of the UK MS Research Group. Cannabinoids for treatment of spasticity
and other symptoms related to multiple sclerosis (CAMS study): multicentre
randomised placebo-controlled trial. Lancet 2003; 362(9385): 1517-1526.
·
Zajicek JP, Sanders HP, Wright DE, Vickery PJ, Ingram WM, Reilly SM,
Nunn AJ, Teare LJ, Fox PJ, Thompson AJ. Cannabinoids in multiple sclerosis
(CAMS) study: safety and efficacy data for 12 months follow up. J Neurol
Neurosurg Psychiatry 2005;76(12):1664-9.
·
Wade DT, Makela PM, House H, Bateman C, Robson P. Long-term use of a
cannabis-based medicine in the treatment of spasticity and other symptoms in
multiple sclerosis. Mult Scler 2006;12(5):639-45.
·
Collin C, Ambler Z, Kent R, McCalla R. A randomised controlled study of
Sativex® in patients with symptoms of spasticity due to multiple sclerosis.
22nd Congress of the ECTRIMS, 27-30 September 2006, Madrid, Spain.
·
Collin C, Davies P, Mutiboko IK, Ratcliffe S, for the Sativex Spasticity
in MS Study Group. Randomized controlled trial of cannabis-based medicine in
spasticity caused by multiple sclerosis. Eur J Neurology 2007;14(3):290–296.
·
Meinck HM, Schönle PWA, Conrad B. Effect of cannabinoids on spasticity
and ataxia in multiple sclerosis. Journal of Neurology 1989;236:120-122.
v
Greenberg HS, Werness SAS, Pugh JE, Andrus RO, Anderson DJ, Domino EF.
Short-term effects of smoking marijuana on balance in patients with multiple
sclerosis and normal volunteers. Clinical Pharmacology and Therapeutics
1994;55:324-328.
·
Deutsch SI, Rosse RB, Connor JM, Burket JA, Murphy ME, Fox FJ. Current status
of cannabis treatment of multiple sclerosis with an illustrative case
presentation of a patient with MS, complex vocal tics, paroxysmal dystonia, and
marijuana dependence treated with dronabinol. CNS Spectr 2008;13(5):393-403.
·
Consroe P, Musty R, Rein J, Tillery W, Pertwee R. The perceived effects
of smoked cannabis on patients with multiple sclerosis. European Neurology
1997;38:44-48.
·
Page SA, Verhoef MJ, Stebbins RA, Metz LM, Levy JC. Cannabis use as
described by people with multiple sclerosis. Can J Neurol Sci 2003;30(3):201-5.
·
Chong MS, Wolff K, Wise K, Tanton C, Winstock A, Silber E. Cannabis use
in patients with multiple sclerosis. Mult Scler 2006;12(5):646-51.
·
Hodges C. Personal account of medical use of cannabis. J Cannabis Ther
2002;2(3-4):155-60.
·
Hanigan WC, Destree R, Truong XT. The effect of D9-THC on human
spasticity. Clinical Pharmacology and Therapeutics 1986;39:198.
·
Maurer M, Henn V, Dittrich A, Hofmann A. Delta-9-tetrahydrocannabinol
shows antispastic and analgesic effects in a single case double-blind trial.
European Archives of Psychiatry and Clinical Neuroscience 1990;240:1-4.
·
Hagenbach U, Luz S, Ghafoor N, Berger JM, Grotenhermen F, Brenneisen R,
Mäder M. The treatment of spasticity with Delta9-tetrahydrocannabinol in
persons with spinal cord injury. Spinal Cord 2007;45(8):551-62.
·
Kogel RW, Johnson PB, Chintam R, Robinson CJ, Nemchausky BA. Treatment of
spasticity in spinal cord injury with dronabinol, a tetrahydrocannabinol
derivative. American Journal of Therapeutics 1995;2(10):799-805.
·
Malec J, Harvey RF, Cayner JJ. Cannabis effect on spasticity in spinal
cord injury. Archives of Physical Medicine and Rehabilitation 1982;63:116-118.
·
Consroe P, Tillery W, Rein J, Musty RE. Reported Marijuana effects in
patients with spinal cord injury. 1998 Symposium on the Cannabinoids.
Burlington: International Cannabinoid Research Society, 1998, p. 64.
·
Dunn M, Davis R. The perceived effects of marijuana on spinal cord
injured males. Paraplegia 1974;12:175.
·
Wade DT, Robson P, House H, Makela P, Aram J. A preliminary controlled
study to determine whether whole-plant cannabis extracts can improve
intractable neurogenic symptoms. Clinical Rehabilition 2003;17:18-26.
·
Brenneisen R, Egli A, Elsohly MA, Henn V, Spiess Y. The effect of orally
and rectally administered delta-9-tetrahydrocannabinol on spasticity: a pilot
study with 2 patients. International Journal of Clinical Pharmacology and
Therapeutics 1996;34:446-452.
·
Lorenz R. A casuistic rationale for the treatment of spastic and
myocloni in a childhood neurodegenerative disease: neuronal ceroid
lipofuscinosis of the type Jansky-Bielschowsky. Neuro Endocrinol Lett
2002;23(5-6):387-90.
·
Petro DJ. Marihuana as a therapeutic agent for muscle spasm or spasticity. Psychosomatics
1980;21:81-85.
·
Randall RC, ed. Muscle Spasm, Pain & Marijuana Therapy. Washington, DC: Galen Press,
1991.
·
Brenneisen R, Egli A, Elsohly MA, Henn V, Spiess Y. The effect of orally
and rectally administered delta-9-tetrahydrocannabinol on spasticity: a pilot
study with 2 patients. International Journal of Clinical Pharmacology and
Therapeutics 1996;34:446-452.
·
Maurer M, Henn V, Dittrich A, Hofmann A. Delta-9-THC shows antispastic
and analgesic effects in a single case double blind trial. European Archives of
Psychiatry and Clinical Neuroscience 1990;240:1-4.
·
Wade DT, Robson P, House H, Makela P, Aram J. A
preliminary controlled study to determine whether whole-plant cannabis extracts
can improve intractable neurogenic symptoms. Clinical Rehabilitation
2003;17:18-26.
·
Berman JS, Symonds C, Birch R. Efficacy of two cannabis based medicinal
extracts for relief of central neuropathic pain from brachial plexus avulsion:
results of a randomised controlled trial. Pain
2004;112(3):299-306.
·
Svendsen KB, Jensen TS,
Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple
sclerosis? Randomised double blind placebo controlled crossover trial. BMJ 2004;329(7460):253.
·
Wissel J, Haydn T,
Müller J, Brenneis C, Berger T, Poewe W, Schelosky LD. Low dose treatment with the
synthetic cannabinoid Nabilone significantly reduces spasticity-related pain : a double-blind placebo-controlled
cross-over trial. J Neurol 2006;253(10):1337-41.
o
Frank B, Serpell MG, Hughes J, Matthews JN, Kapur D. Comparison of
analgesic effects and patient tolerability of nabilone and dihydrocodeine for
chronic neuropathic pain: randomised, crossover, double blind study. BMJ 2008;336(7637):199-201.
·
Wade DT, Robson P, House H, Makela P, Aram J. A preliminary controlled study
to determine whether whole-plant cannabis extracts can improve intractable
neurogenic symptoms. Clinical Rehabilitation 2003;17:18-26.
·
Berman J, Lee J, Cooper M, Cannon A, Sach J, McKerral S, Taggart M,
Symonds C, Fishel K, Birch R. Efficacy of two cannabis-based medicinal extracts
for relief of central neuropathic pain from brachial plexus avulsion: results
of a randomised controlled trial. Anaesthesia, 2003;58:938.
·
Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of
cannabis-based medicine in central pain in multiple sclerosis. Neurology
2005;65(6):812-9.
o
Ernst G, Denke C, Reif M, Schnelle M, Hagmeister H. Standardized
cannabis extract in the treatment of postherpetic neuralgia: a randomized,
double-blind, placebo-controlled cross-over study. IACM 3rd Conference on
Cannabinoids in Medicine, 9-10 September 2005, Leiden, International
Association for Cannabis as Medicine.
·
Nurmikko TJ, Serpell MG, Hoggart B, Toomey PJ, Morlion BJ, Haines D.
Sativex successfully treats neuropathic pain characterised by allodynia: a
randomised, double-blind, placebo-controlled clinical trial. Pain
2007;133(1-3):210-20.
·
Abrams DI, Jay CA, Shade SB, Vizoso H, Reda H, Press S, Kelly ME,
Rowbotham MC, Petersen KL. Cannabis in painful HIV-associated sensory
neuropathy: A randomized placebo-controlled trial. Neurology 2007;68(7):515-21.
·
Wilsey B, Marcotte T, Tsodikov A, Millman J, Bentley H, Gouaux B,
Fishman S. A randomized, placebo-controlled, crossover trial of cannabis
cigarettes in neuropathic pain. J Pain 2008;9(6):506-21.
o
Lindstrom P, Lindblom U, Boreus L. Lack of effect of cannabidiol in
sustained neuropathia. Paper presented at '87 International Conference on
Cannabis, Melbourne, September 2-4, 1987. Cited from: Consroe P, Sandyk R.
Potential role of cannabinoids for therapy of neurological disorders. In: Murphy L,
Bartke A, eds. Marijuana/Cannabinoids. Neurobiology and Neurophysiology. Boca
Raton, CRC Press, 1992:459-524.
·
Karst M, Salim K, Burstein S, Conrad I, Hoy L, Schneider U. Analgesic
effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a
randomized controlled trial. JAMA 2003;290(13):1757-62.
o
Clermont-Gnamien S, Atlani S, Attal N, Le Mercier F, Guirimand F,
Brasseur L. [The therapeutic use of D9-tetrahydrocannabinol (dronabinol) in
refractory neuropathic pain] [Article in French] Presse Med 2002;31(39 Pt
1):1840-5.
·
Finnegan-Ling D, Musty RE. Marinol and phantom limb pain; a case study.
In: 1994 Symposium on the Cannabinoids. Burlington, Vermont: International
Cannabinoid Research Society, p. 53.
o
Attal N, Brasseur L, Guirimand D, Clermond-Gnamien S, Atlami S,
Bouhassira D. Are oral cannabinoids safe and effective in refractory
neuropathic pain? Eur J Pain 2004;8:173–177.
·
Rog DJ, Nurmikko TJ, Young CA. Oromucosal
delta-9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with
multiple sclerosis: an uncontrolled, open-label, 2-year extension trial. Clin
Ther 2007;29(9):2068-79.
·
Dunn M, Davis R. The perceived effects of marijuana on spinal cord
injured males. Paraplegia 1974;12:175.
·
Consroe P, Musty R, Rein J, Tillery W, Pertwee R. The perceived effects of
smoked cannabis on patients with multiple sclerosis. European Neurology 1997;38:44-48.
·
Petro DJ. Marihuana as a therapeutic agent for muscle spasm or
spasticity. Psychosomatics 1980;21:81-85.
·
Page SA, Verhoef MJ, Stebbins RA, Metz LM, Levy JC. Cannabis use as
described by people with multiple sclerosis. Can J Neurol Sci 2003;30(3):201-5.
·
Prentiss D, Power R,
Balmas G, Tzuang G, Israelski DM. Patterns of marijuana use among patients with
HIV/AIDS followed in a public health care setting. J Acquir Immune Defic Syndr
2004;35(1):38-45.
·
Woolridge E, Barton S, Samuel J, Osorio J, Dougherty A, Holdcroft A.
Cannabis use in HIV for pain and other medical symptoms. J Pain Symptom Manage
2005;29(4):358-67.
·
Chong MS, Wolff K, Wise K, Tanton C, Winstock A, Silber E. Cannabis use
in patients with multiple sclerosis. Mult Scler 2006;12(5):646-51.
·
Noyes R, Brunk SF, Baram DA, Canter A. Analgesic effects of delta-9-THC.
Journal of Clinical Pharmacology 1975;15:139-143.
·
Noyes R, Brunk ST, Avery DH, Canter A. The analgesic properties of
delta-9-tetrahydrocannabinol and codeine. Clinical Pharmacology and
Therapeutics 1975;18:84-89.
o
Johnson JR, Potts R. Cannabis-based medicines in the treatment of cancer
pain: a randomised, double-blind, parallel group, placebo controlled,
comparative study of the efficacy, safety and tolerability of Sativex and
Tetranabinex in patients with cancer-related pain. British Pain Society; 2005
March 8-11; Edinburgh, Scotland.
·
Johnson JR, Potts R. Cannabis-based medicines in the treatment of cancer
pain: a randomised, double-blind, parallel group, placebo controlled,
comparative study of the efficacy, safety and tolerability of Sativex and
Tetranabinex in patients with cancer-related pain. British Pain Society; 2005
March 8-11; Edinburgh, Scotland.
o
Jochimsen PR, Lawton RL, VerSteeg K, Noyes Jr R. Effect of
benzopyranoperidine, a delta-9-THC congener, on pain. Clinical Pharmacology and
Therapeutics 1978;24:223-7.
·
Staquet M, Gantt C, Machin D. Effect of a nitrogen analog of
tetrahydrocannabinol on cancer pain. Clinical Pharmacology and Therapeutics 1978;23:397-401.
·
Butler JR Peek LA Regelson W
Moore MM Lubin LA. Treatment
effects of delta-9-THC in an advanced cancer population. In: Cohen S, Stillman
RC, eds. The therapeutic potential of marihuana. Plenum Medical Book, New York
1976.
·
Maida V. The synthetic cannabinoid nabilone improves
pain and symptom management in cancer patients. Abstract of San Antonio Breast
Cancer Symposium, 15 December 2006.
·
Maida V, Ennis M, Irani S, Corbo M, Dolzhykov M. Adjunctive nabilone in
cancer pain and symptom management: a prospective observational study using
propensity scoring. J Support Oncol 2008;6(3):119-24.
·
Blake DR, Robson P, Ho M, Jubb RW, McCabe CS. Preliminary assessment of
the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in
the treatment of pain caused by rheumatoid arthritis. Rheumatology (Oxford)
2006;45(1):50-2.
·
Skrabek RQ, Galimova L, Ethans K, Perry D. Nabilone for the treatment of
pain in fibromyalgia. J Pain 2008;9(2):164-73.
·
Schley M, Legler A, Skopp G, Schmelz M, Konrad C, Rukwied R. Delta-9-THC
based monotherapy in fibromyalgia patients on experimentally induced pain, axon
reflex flare, and pain relief. Curr Med Res Opin 2006;22(7):1269-1276.
·
Fiz J, Duran M, Langohr K, Capellà D, Farré M. Symptoms relief and
improved mental health in fibromyalgia patients using cannabis. Results of an
observational study. IACM 4th Conference on Cannabinoids in Medicine, 5-6
October 2007, Cologne, International Association for Cannabis as Medicine.
·
Notcutt W, Price M, Miller R, Newport S,
Phillips C, Simmons S, Sansom C. Initial experiences with medicinal extracts of
cannabis for chronic pain: results from 34 'N of 1' studies. Anaesthesia 2004;59(5):440-52.
·
Narang S, Gibson D, Wasan AD, Ross EL, Michna E, Nedeljkovic SS, Jamison
RN. Efficacy of dronabinol as an adjuvant treatment for chronic pain patients
on opioid therapy. J Pain 2008;9(3):254-64.
·
Holdcroft A, Smith M, Jacklin A, Hodgson H, Smith B, Newton M, Evans F. Pain
relief with oral cannabinoids in familial Mediterranean fever. Anaesthesia
1997;52:483-488.
·
Notcutt W, Price M, Miller R, Newport S, Phillips C, Simmons S, Sansom
C. Initial experiences with medicinal extracts of cannabis for chronic pain:
results from 34 'N of 1' studies. Anaesthesia 2004;59(5):440-52.
·
Ware MA, Ducruet T, Robinson AR. Evaluation of herbal cannabis characteristics
by medical users: a randomized trial. Harm Reduct J 2006;3(1):32
·
Pinsger M, Schimetta W, Volc D, Hiermann E, Riederer F, Polz W.
[Benefits of an add-on treatment with the synthetic cannabinomimetic nabilone
on patients with chronic pain - a randomized controlled trial.] [Article in German] Wien Klin Wochenschr
2006;118(11-12):327-35.
·
Hamann W, di Vadi PP. Analgesic
effect of the cannabinoid analogue nabilone is not mediated by opioid
receptors. Lancet 1999;353(9152):560.
·
Elsner F, Radbruch L, Sabatowski R. [Tetrahydrocannabinol for treatment
of chronic pain] [Article in German]. Pain 2001;15(3):200-4.
·
Noyes R, Baram DA. Cannabis analgesia. Comprehensive Psychiatry
1974:15:531-535.
·
Ware MA, Doyle CR, Woods R, Lynch ME, Clark AJ. Cannabis use for chronic
non-cancer pain: results of a prospective survey. Pain 2003;102(1-2):211-216.
·
Lynch ME, Clark AJ. Cannabis reduces opioid dose in the treatment of
chronic non-cancer pain. J Pain Symptom Manage 2003;25(6):496-8.
·
Howard J, Anie KA, Holdcroft A, Korn S, Davies SC. Cannabis use in
sickle cell disease: a questionnaire study. Br J Haematol 2005;131(1):123-8.
·
Russo EB, Mathre ML, Byrne A, Velin R, Bach PJ, Sanchez-Ramos J, et al.
Chronic cannabis use in the Compassionate Investigational New Drug Program: An
examination of benefits and adverse effects of legal clinical cannabis. J
Cannabis Ther 2002;2(1):3-57.
o
Raft D, Gregg J, Ghia J, Harris L. Effects of intravenous tetrahydrocannabinol
on experimental and surgical pain: psychological correlates of the analgesic
response. Clinical Pharmacology and Therapeutics 1977;21:26-33.
o
Buggy DJ, Toogood L, Maric S, Sharpe P, Lambert DG, Rowbotham DJ. Lack of
analgesic efficacy of oral delta-9-tetrahydrocannabinol in postoperative pain.
Pain 2003;106(1-2):169-72.
o
Seeling W, Kneer L, Buchele B, Gschwend JE, Maier L, Nett C, Simmet T,
Steffen P, Schneider M, Rockemann M. [(9)-tetrahydrocannabinol and the opioid
receptor agonist piritramide do not act synergistically in postoperative pain.]
[Article in
German]. Anaesthesist 2006;55(4):391-400.
·
Holdcroft A, Maze M, Dore C, Tebbs S, Thompson S. A multicenter
dose-escalation study of the analgesic and adverse effects of an oral cannabis
extract (Cannador) for postoperative pain management. Anesthesiology
2006;104(5):1040-1046.
o
Beaulieu P. Effects of nabilone, a synthetic cannabinoid, on
postoperative pain. Can J Anaesth 2006;53(8):769-75.
·
Jain AK, Ryan JR, McMahon FG, Smith G. Evaluation of intramuscular
levonantradol and placebo in acute postoperative pain. Journal of Clinical
Pharmacology 1981;21(suppl 8-9):S320-S326.
·
Kantor TG, Hopper M. A study of levonantradol, a cannabinol derivative,
for analgesia in post operative pain. Pain 1981; (suppl): S37.
o
Naef M, Curatolo M, Petersen-Felix S, Arendt-Nielsen L, Zbinden A,
Brenneisen R. The analgesic effect of oral delta-9-tetrahydrocannabinol (THC),
morphine, and a THC-morphine combination in healthy subjects under experimental
pain conditions. Pain 2003;105(1-2):79-88.
·
Roberts JD, Gennings C, Shih M. Synergistic affective analgesic
interaction between delta-9-tetrahydrocannabinol and morphine. Eur J Pharmacol
2006;530(1-2):54-8.
o
Redmond WJ, Goffaux P, Potvin S, Marchand S. Analgesic and antihyperalgesic effects of nabilone on
experimental heat pain. Curr Med Res
Opin 2008;24(4):1017-24.
·
Greenwald MK, Stitzer ML Antinociceptive, subjective and behavioral
effects of smoked marijuana in humans. Drug Alcohol Depend 2000;59(3):261-75.
·
Wallace M, Schulteis G, Atkinson JH, Wolfson T, Lazzaretto D, Bentley H,
Gouaux B, Abramson I. Dose-dependent effects of smoked cannabis on
capsaicin-induced pain and hyperalgesia in healthy volunteers. Anesthesiology
2007;107(5):785-796.
o
Hill SY, Schwin R, Goodwin DW, Powell B.
Marihuana and pain. J Pharmacol Exp Ther 1974;188:415-8.
o
Clark
WC, Janal MN, Zeidenberg P, Nahas GG. Effects of moderate
and high doses of marihuana on thermal pain: a sensory decision theory
analysis. J Clin Pharmacol 1981;21(8-9 Suppl):299S-310S.
·
Raby WN, Modica PA, Wolintz RJ, Murtaugh K. Dronabinol reduces signs and
symptoms of idiopathic intracranial hypertension: a case report. J Ocul Pharmacol
Ther 2006;22(1):68-75.
·
Mortati K, Dworetzky B, Devinsky O. Marijuana: an effective
antiepileptic treatment in partial epilepsy? A case report and review of the
literature. Rev Neurol Dis 2007;4(2):103-6.
·
Raby WN, Modica PA, Wolintz RJ, Murtaugh K. Dronabinol reduces signs and
symptoms of idiopathic intracranial hypertension: a case report. J Ocul
Pharmacol Ther 2006;22(1):68-75.
·
Russo EB. Hemp for headache: An in-depth historical and scientific review of
cannabis in migraine treatment. J Cannabis Ther 2001;1(2):21-92.
·
Amtmann D, Weydt P, Johnson KL, Jensen MP, Carter GT. Survey of cannabis
use in patients with amyotrophic lateral sclerosis. Am J Hosp Palliat Care
2004;21(2):95-104.
·
Hagenbach U, Ghafoor N, Brenneisen R, Luz S, Mäder M. Clinical
investigation of D-9-tetrahydrocannabinol
(THC) as an alternative therapy for overactive bladders in spinal cord injury
(SCI) patients? Abstract, 2001 Congress on Cannabis and the Cannabinoids,
International Association for Cannabis as Medicine, 25-27 October 2001,
Cologne, Germany.
·
Brady CM, DasGupta R, Dalton C, Wiseman OJ, Berkley KJ, Fowler CJ. An open-label
pilot study of cannabis-based extracts for bladder dysfunction in advanced
multiple sclerosis. Multiple Sclerosis 2004;10(4):425-33.
·
de Ridder D, Constantinescu CS,Fowler C, Kavia R, Sarantis N. Randomised
controlled study of cannabis-based medicine (Sativex®) in patients suffering
from multiple sclerosis associated detrusor overactivity. 22nd Congress of the
ECTRIMS, 27-30 September 2006, Madrid, Spain.
·
Esfandyari T, Camilleri M, Busciglio I, Burton D, Baxter K, Zinsmeister AR.
Effects
of a cannabinoid receptor agonist on colonic motor and sensory functions in humans: a randomized, placebo-controlled study.
Am J Physiol Gastrointest Liver Physiol 2007;293(1):G137-45.
·
Russo E. Cannabis treatments in obstetrics and gynecology: A historical
review. J Cannabis Ther 2002;2(3-4):5-35.
·
Clifford DB. Tetrahydrocannabinol for tremor in multiple sclerosis.
Annals of Neurology 1983;13:669-671.
o
Fox P, Bain PG, Glickman S, Carroll C, Zajicek J. The effect of cannabis
on tremor in patients with multiple sclerosis. Neurology 2004;62(7):1105-9.
o
Fox SH, Kellett M, Moore AP, Crossman AR, Brotchie JM. Randomised,
double-blind, placebo-controlled trial to assess the potential of cannabinoid
receptor stimulation in the treatment of dystonia. Movement Disorders
2002;17(1):145-149.
·
Snider SR, Consroe P. Treatment of Meige's syndrome with cannabidiol.
Neurology 1984;34(Suppl):147.
·
Sandyk R, Snider SR, Consroe P, Elias SM. Cannabidiol in dystonic
movement disorders. Psychiatry Research 1986;18:291.
·
Consroe P, Sandyk R, Snider SR. Open label evaluation of cannabidiol in
dystonic movement disorders. International Journal of Neuroscience 1986;30:277-282.
·
Sieradzan KA, Fox SH, Dick J, Brotchie JM. The effects of the cannabinoid
receptor agonist nabilone on L-DOPA induced dyskinesia in patients with
idiopathic Parkinson's disease (PD). Movement Disorders 1998;13(Suppl 2):29.
·
Gilson I, Busalacchi M. Marijuana for intractable hiccups. Lancet 1998; 351(9098):
267.
·
Müller-Vahl KR, Schneider U, Koblenz A, Jobges M, Kolbe H, Daldrup T,
Emrich HM. Treatment of Tourette's syndrome with Delta 9-tetrahydrocannabinol
(THC): a randomized crossover trial. Pharmacopsychiatry 2002;35(2):57-61.
·
Müller-Vahl KR, Schneider U, Prevedel H, Theloe K, Kolbe H, Daldrup T,
Emrich HM. Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of
tics in Tourette syndrome: a 6-week randomized trial. Journal of Clinical
Psychiatry. 2003;64(4):459-65.
·
Müller-Vahl KR,
Schneider U, Kolbe H, Emrich HM. Treatment of Tourette-Syndrome with
delta-9-Tetrahydrocannabinol. American Journal of Psychiatry 1999;156:495.
·
Deutsch SI, Rosse RB, Connor JM, Burket JA, Murphy ME, Fox FJ. Current
status of cannabis treatment of multiple sclerosis with an illustrative case
presentation of a patient with MS, complex vocal tics, paroxysmal dystonia, and
marijuana dependence treated with dronabinol. CNS Spectr 2008;13(5):393-403.
·
Müller-Vahl KR,
Schneider U, Emrich HM. Combined treatment of Tourette syndrome with
delta-9-THC and dopamine receptor agonists. J Cannabis Ther 2002;2(3-4):145-54.
·
Müller-Vahl KR, Kolbe H,
Schneider U, Emrich HM. Cannabinoids: Possible role in pathophysiology of Gilles
de la Tourette-syndrome. Acta Psychiatrica Scandinavica 1998;97:1-5.
·
Sandyk R, Awerbuch G. Marijuana and Tourette's Syndrome. Journal of
Clinical Psychopharmacology 1988;8:444-445.
·
Hemming M, Yellowlees PM. Effective treatment of Tourette's syndrome
with marijuana. J Psychopharmacol 1993; 7: 389-91.
·
Aharonovich E, Garawi F, Bisaga A, Brooks D, Raby WN, Rubin E, Nunes EV,
Levin FR. Concurrent cannabis use during treatment for comorbid ADHD and cocaine
dependence: effects on outcome. Am J Drug Alcohol Abuse. 2006;32(4):629-35.
·
Strohbeck-Kuehner P, Skopp G, Mattern R. [Fitness to drive in spite (because)
of THC] [Article in German]. Arch Kriminol 2007;220(1-2):11-9.
·
Strohbeck-Kuehner P, Skopp G, Mattern R. [Fitness to drive in spite
(because) of THC] [Article in German]. Arch Kriminol
2007;220(1-2):11-9.
·
O'Connell TJ, Bou-Matar CB. Long term marijuana users seeking medical
cannabis in California (2001-2007): demographics, social characteristics,
patterns of cannabis and other drug use of
4117 applicants. Harm Reduct J 2007;4:16.
·
Schindler F, Anghelescu I, Regen F, Jockers-Scherubl M. Improvement in
refractory obsessive compulsive disorder with dronabinol. Am J Psychiatry 2008;165(4):536-7.
o
Carroll CB, Bain PG, Teare L, Liu X, Joint C, Wroath C, Parkin SG, Fox
P, Wright D, Hobart J, Zajicek JP.
Cannabis for dyskinesia in Parkinson disease: a randomized double-blind
crossover study. Neurology 2004;63(7):1245-50.
o
Frankel JP, Hughes A, Lees AJ, Stern GM. Marijuana for Parkinsonian
tremor. Journal of Neurology, Neurosurgery and Psychiatry 1990;53:436.
o
Consroe P, Laguna J, Allender J, Snider S, Stern L, Sandyk R, Kennedy K,
Schram K. Controlled clincal trial of cannabidiol in Huntington's disease.
Pharmacology, Biochemistry and Behavior. 1991;40(3):701-8.
v
Müller-Vahl KR,
Schneider U, Emrich HM. Nabilone deteriorates choreatic movements in
Huntington`s disease. Movement Disorders 1999b;14:1038-40.
o
Maas AI, Murray G, Henney H 3rd, Kassem N, Legrand V, Mangelus M, Muizelaar
JP, Stocchetti N, Knoller N; Pharmos TBI investigators. Efficacy and safety
of dexanabinol in severe traumatic brain injury: results of a phase III
randomised, placebo-controlled, clinical trial. Lancet Neurol 2006;5(1):38-45.
·
Raby WN, Modica PA, Wolintz RJ, Murtaugh K. Dronabinol reduces signs and
symptoms of idiopathic intracranial hypertension: a case report. J Ocul
Pharmacol Ther 2006;22(1):68-75.
·
Szepietowski JC, Szepietowski T, Reich A. Efficacy and tolerance of the
cream containing structured physiological lipids with endocannabinoids in the
treatment of uremic pruritus: a preliminary study. Acta Dermatovenerol Croat
2005;13(2):97-103.
·
Ständer S, Reinhardt HW,
Luger TA. [Topical cannabinoid agonists: An effective new possibility for treating
chronic pruritus.] [Article in German]. Hautarzt 2006;57(9):801-7.
·
Neff GW, O'Brien CB, Reddy KR, Bergasa NV, Regev A, Molina E, Amaro R,
Rodriguez MJ, Chase V, Jeffers L,
Schiff E. Preliminary observation with dronabinol in patients with intractable
pruritus secondary to cholestatic liver disease. Am J Gastroenterol 2002;97(8):2117-9.
·
Cunha JM, Carlini EA, Pereira AE, Ramos OL, Pimentel C, Gagliardi R,
Sanvito WL, Lander N, Mechoulam R. Chronic administration of cannabidiol to
healthy volunteers and epileptic patients. Pharmacology 1980;21(3):175-85.
·
Consroe PF, Wood GC, Buchsbaum H. Anticonvulsant nature of marihuana
smoking. JAMA 1975;234(3):306-7.
o
Ames FR, Cridland S.: Anticonvulsant effect of cannabidiol [letter]. South
African Medical Journal 1986;69:14.
o
Trembly B, Sherman M. Double-blind clinical study of cannabidiol as a
secondary anticonvulsant. Conference on Cannabis and Cannabinoids,
Kolympari/Crete, July 1990, cited according to: Consroe P, Sandyk R. Potential
role of cannabinoids for therapy of neurological disorders. In: Murphy L,
Bartke A, eds. Marijuana/Cannabinoids, Neurobiology and Neurophysiology. Boca
Raton: CRC Press 1992, 459-524. [Commentary: No effect of Cannabidiol
(300 mg/day) in 10 patients.]
·
Trembly B, Sherman M. Double-blind clinical study of cannabidiol as a
secondary anticonvulsant. Conference on Cannabis and Cannabinoids,
Kolympari/Crete, July 1990, cited according to: Consroe P, Sandyk R. Potential
role of cannabinoids for therapy of neurological disorders. In: Murphy L,
Bartke A, eds. Marijuana/Cannabinoids, Neurobiology and Neurophysiology. Boca
Raton: CRC Press 1992, 459-524. [Commentary: Reduction in Reduzierung in
frequency of seizures with cannabidiol (900-1200 mg/day) in one patient.]
·
Corral VL. Differential effects of medical marijuana based on strain and route of
administration: A three-year observational study. J Cannabis Ther
2001;1(3-4):43-59.
·
Crawford WJ, Merritt JC. Effects of tetrahydrocannabinol on arterial and
intraocular hypertension. International Journal of Clinical Pharmacololgy and
Biopharmacy 1979;17(5):191-196.
·
Merritt JC, Crawford WJ, Alexander PC, Anduze AL, Gelbart SS. Effect of
marihuana on intraocular and blood pressure in glaucoma. Ophthalmology
1980;87(3):222-8.
·
Tomida I, Azuara-Blanco A, House H, Flint M, Pertwee RG, Robson PJ.
Effect of sublingual application of cannabinoids on intraocular pressure: a
pilot study. J Glaucoma 2006;15(5):349-353.
o
Tomida I, Azuara-Blanco A, House H, Flint M, Pertwee RG, Robson PJ.
Effect of sublingual application of cannabinoids on intraocular pressure: a
pilot study. J Glaucoma 2006;15(5):349-353.
·
Hepler RS, Frank IM, Petrus R. Ocular effects of marijuana smoking. In:
Braude MC, Szara S, eds. The pharmacology of marihuana. Raven Press: New York:
1976;815-828.
·
Russo EB, Mathre ML, Byrne A, Velin R, Bach PJ, Sanchez-Ramos J, et al.
Chronic cannabis use in the Compassionate Investigational New Drug Program: An
examination of benefits and adverse effects of legal clinical cannabis. J
Cannabis Ther 2002;2(1):3-57.
o
Merritt JC, Perry DD, Russell DN, Jones BF. Topical delta
9-tetrahydrocannabinol and aqueous dynamics in glaucoma. Journal of Clinical
Pharmacololgy 1981;21(8-9 Suppl):467S-471S.
·
Cooler P, Gregg JM. Effect of delta-9-tetrahydrocannabinol on intraocular
pressure in humans. Southern Medical Journal 1977;70(8):951-954.
·
Jones RT, Benowitz N, Herning RI. The clinical relevance of cannabis
tolerance and dependence. Journal of Clinical Pharmacology 1981;21:143S-152S.
o
Levitt M, Wilson A, Bowman D, Kemel S, Krepart G, Marks V, Schipper H,
Thomson G, Weinerman B, Weinerman R. Physiologic observations in a controlled clinical
trial of the antiemetic effectiveness of 5, 10, and 15 mg of delta
9-tetrahydrocannabinol in cancer chemotherapy. Ophthalmologic implications. J
Clin Pharmacol 1981;21(8-9 Suppl):103S-109S.
·
Perez-Reyes M, Wagner D, Wall ME. Davis KH. Intravenous administration
of cannabinoids and intraocular pressure. In: Braude MC, Szara S, ed. Pharmacology of
marihuana. New York: Raven Press, 1976;829-832.
·
Plange N, Arend KO, Kaup M, Doehmen B, Adams H, Hendricks S, Cordes A,
Huth J, Sponsel WE, Remky A. Dronabinol and retinal hemodynamics in humans. Am J Ophthalmol 2007;143(1):173-4.
·
Hepler RS, Frank IM. Marihuana smoking and intraocular pressure. Journal
of the American Medical Association 1971;217:1392.
·
Flom MC, Adams AJ, Jones RT. Marijuana smoking and reduced intraocular
pressure in human eye: Drug action or epiphenomenon? Investigative
Ophthalmology 1975;14:52-55.
·
Hepler R S, Frank I M, Petrus R. Ocular effects of marijuana smoking.
In: Braude MC, Szara S, eds. The pharmacology of marihuana. New York: Raven
Press, 1976;815-828.
·
Russo EB, Merzouki A, Molero Mesa J, Frey KA, Bach PJ. Cannabis improves night
vision: A pilot study of dark adaptometry and scotopic sensitivity in kif
smokers of the Rif Mountains of Northern Morocco. J Ethnopharmacol
2004;93(1):99-104.
·
Russo EB, Merzouki A, Molero Mesa J, Frey KA, Bach PJ. Cannabis improves
night vision: A pilot study of dark adaptometry and scotopic sensitivity in kif
smokers of the Rif Mountains of Northern Morocco. J Ethnopharmacol
2004;93(1):99-104.
·
Tashkin DP, Reiss S, Shapiro BJ, Calvarese B, Olsen JL, Lodge JW.
Bronchial effects of aerosolized delta 9-tetrahydrocannabinol in healthy and
asthmatic subjects. American Review of Respiratory Disease 1977;115(1):57-65.
·
Williams SJ, Hartley JP, Graham JD. Bronchodilator effect of
delta1-tetrahydrocannabinol administered by aerosol of asthmatic patients.
Thorax 1976;31(6):720-723.
·
Tashkin DP, Shapiro BJ, Lee YE, Harper CE. Effects of smoked marijuana
in experimentally induced asthma. American Review of Respiratory Disease
1975;112(3):377-386.
·
Vachon L, Mikus P, Morrissey W, FitzGerald M, Gaensler E. Bronchial
effect of marihuana smoke in asthma. In: Braude MC, Szara S, eds. The pharmacology
of marihuana. Raven Press: New York: 1976;777-784.
o
Gong H Jr, Tashkin DP, Calvarese B. Comparison of bronchial effects of
nabilone and terbutaline in healthy and asthmatic subjects. Journal of Clinical
Pharmacology 1983;23(4):127-133
·
Tashkin DP, Shapiro BJ,
Frank IM. Acute effects of smoked marijuana and oral delta9-tetrahydrocannabinol
on specific airway conductance in asthmatic subjects. American Review for
Respiratory Diseases. 1974 Apr;109(4):420-8.
·
Tashkin DP, Shapiro BJ, Frank IM. Acute effects of smoked marijuana and
oral delta9-tetrahydrocannabinol on specific airway conductance in asthmatic
subjects. American Review for Respiratory Diseases 1974 Apr;109(4):420-8.
·
Gong H Jr, Tashkin DP, Simmons MS, Calvarese B, Shapiro BJ. Acute and
subacute bronchial effects of oral cannabinoids. Clinical Pharmacology and
Therapeutics 1984;35(1):26-32.
·
Tashkin DP, Reiss S, Shapiro BJ, Calvarese B, Olsen JL, Lodge JW.
Bronchial effects of aerosolized delta 9-tetrahydrocannabinol in healthy and
asthmatic subjects. American Review of Respiratory Disease 1977;115(1):57-65.
·
Gong H Jr, Tashkin DP, Calvarese B. Comparison of bronchial effects of
nabilone and terbutaline in healthy and asthmatic subjects. Journal of Clinical
Pharmacology 1983;23(4):127-133.
·
Guzmán M, Duarte MJ, Blázquez C, Ravina J, Rosa MC, Galve-Roperh I, Sánchez
C, Velasco G, González-Feria L. A pilot clinical study of Delta9-tetrahydrocannabinol
in patients with recurrent glioblastoma multiforme. Br J Cancer
2006;95(2):197-203.
·
Volicer L, Stelly M, Morris J, McLaughlin J, Volicer BJ. Effects of dronabinol
on anorexia and disturbed behavior in patients with Alzheimer's disease.
International Journal of Geriatric Psychiatry 1997;12:913-919.
·
Patel S, Shua-Haim JR, Pass M. Safety and efficacy of dronabinol in the
treatment of agitation in patients with Alzheimer’s disease with anorexia: A
retrospective chart review. Abstract, 11th International Conference of the IPA,
17-22 August 2003, Chicago.
·
Ross JS, Shua-Haim JR. Open-label study of dronabinol in the treatment of
refractory agitation in Alzheimer’s disease: a pilot study. Abstract, ASCP's
34th Annual Meeting, 12-15 November 2003, San Antonio, USA.
·
Walther S, Mahlberg R, Eichmann U, Kunz D. Delta-9-tetrahydrocannabinol
for nighttime agitation in severe dementia. Psychopharmacology (Berl)
2006;185(4):524-8.
·
Leweke FM, Koethe D, Gerth CW, Nolden BM, Schreiber D, Hänsel A, Neatby
MA, Juelicher A, Hellmich M, Klosterkötter J. Cannabidiol as an antipsychotic. A double-blind,
controlled clinical trial on cannabidiol vs. amisulpride in acute
schizophrenia. IACM 3rd Conference on Cannabinoids in Medicine, 9-10 September
2005, Leiden, International Association for Cannabis as Medicine.
o
Zuardi AW, Hallak JE, Dursun SM, Morais SL, Faria Sanches R, Musty RE,
Crippa JA. Cannabidiol monotherapy for treatment-resistant schizophrenia. J Psychopharmacol
2006;20(5):683-6.
·
Zuardi AW, Morais SL, Guimarães FS, Mechoulam R. Antipsychotic effect of
cannabidiol. Journal of Clinical Psychiatry 1995;56:485-486.
·
Grinspoon L, Bakalar JB. The use of cannabis as a mood stabilizer in
bipolar disorder: anecdotal evidence and the need for clinical research.
Journal of Psychoactive Drugs 1998;30(2):171-7.
o
El-Mallakh RS, Brown C. The effect of extreme marijuana use on the
long-term course of bipolar I illness: a single case study. J Psychoactive Drugs
2007;39(2):201-2.
·
Regelson W, Butler JR, Schulz J, Kirk T, Peek L, Green ML, Zalis MO. Delta-9-tetrahydrocannabinol
as an effective antidepressant and appetite-stimulating agent in advanced
cancer patients. In: Braude MC, Szara S, editors. Pharmacology of marihuana.
Vol 2. New York: Raven Press, 1976. p. 763-776.
·
Ware MA, Adams H, Guy GW. The medicinal use of cannabis in the UK:
results of a nationwide survey. Int J Clin Pract 2005;59(3):291-5.
·
Mikuriya TH. Cannabis substitution. An adjunctive therapeutic tool in
the treatment of alcoholism. Medical Times 1970;98(4):187-91.
·
Mikuriya TH. Cannabis as a substitute for alcohol: a harm-reduction
approach. J Cannabis Ther 2004;4(1):79-93.
o
Hermann D, Klages E, Welzel H, Mann K, Croissant B. Low efficacy of
non-opioid drugs in opioid withdrawal symptoms. Addict Biol 2005;10(2):165-9.
·
O'Connell TJ, Bou-Matar CB. Long term marijuana users seeking medical
cannabis in California (2001-2007): demographics, social characteristics,
patterns of cannabis and other drug use of
4117 applicants. Harm Reduct J 2007;4:16.
·
Aharonovich E, Garawi F, Bisaga A, Brooks D, Raby WN, Rubin E, Nunes EV,
Levin FR. Concurrent cannabis use during treatment for comorbid ADHD and cocaine
dependence: effects on outcome. Am J Drug Alcohol Abuse. 2006;32(4):629-35.
·
Labigalini E Jr, Rodrigues LR, Da Silveira DX. Therapeutic use of cannabis by
crack addicts in Brazil. J Psychoactive Drugs 1999;31(4):451-5.
·
Dreher M. Crack heads and roots daughters: The therapeutic use of
cannabis in Jamaica. J Cannabis Ther 2002;2(3-4):121-33.
·
Haney M, Hart CL, Vosburg SK, Nasser J, Bennett A, Zubaran C, Foltin RW.
Marijuana withdrawal in humans: effects of oral THC or divalproex. Neuropsychopharmacology
2004;29(1):158-70.
·
Levin FR, Kleber HD. Use of dronabinol for cannabis dependence: two case
reports and review. Am J Addict 2008;17(2):161-4.
·
Nicholson AN, Turner C, Stone BM, Robson PJ. Effect of
Delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and
early-morning behavior in young adults. J Clin Psychopharmacol 2004;24(3):305-13.
·
Grinspoon L, Bakalar JB. Marihuana, the forbidden medicine. Rev. and
exp. ed. New Haven: Yale University Press; 1997.
·
Randall RC, O'Leary AM. Marijuana Rx: The patients' fight for medicinal
pot. New York: Thunder's Mouth Press; 1998.
·
Corral VL. Differential effects of medical marijuana based on strain and
route of administration: A three-year observational study. J Cannabis Ther
2001;1(3-4):43-59.
·
Grotenhermen F, Schnelle M. Survey on the medical use of cannabis and
THC in Germany. J Cannabis Ther 2003;3(2):17-40.
·
Gieringer D. Medical use of cannabis: Experience in California. In: Grotenhermen F, Russo
E, editors. Cannabis and cannabinoids: Pharmacology, toxicology, and therapeutic
potential. Binghamton, NY: Haworth Press; 2001. p. 153-70.
·
Ware MA, Adams H, Guy GW. The medicinal use of cannabis in the UK:
results of a nationwide survey. Int J Clin Pract 2005;59(3):291-5.
·
Russo EB, Mathre ML, Byrne A, Velin R, Bach PJ, Sanchez-Ramos J, et al.
Chronic cannabis use in the Compassionate Investigational New Drug Program: An
examination of benefits and adverse effects of legal clinical cannabis. J
Cannabis Ther 2002;2(1):3-57.
·
O'Connell TJ, Bou-Matar CB. Long term marijuana users seeking medical cannabis in
California (2001-2007): demographics, social characteristics, patterns of
cannabis and other drug use of 4117
applicants. Harm Reduct J 2007;4:16.